FDA approves storage, transport of Pfizer-BioNTech vaccine at higher temperatures

Feb 25 (Reuters) - The U.S. Food and Drug Administration on Thursday approved storage and transportation of COVID-19 vaccine developed by Pfizer Inc (PFE.N) and German partner BioNTech SE (22UAy.DE) at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.

Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur

Our Standards: The Thomson Reuters Trust Principles.